akkermansia muciniphila
Phase 1- Indications
- Metabolic disorders, Inflammatory conditions
Company intelligence / Profile preview
A-Mansia’s lead product—pasteurised Akkermansia muciniphila—received EFSA approval as a novel food ingredient. Human studies have shown it can help prevent deterioration of metabolic health in at-risk subjects by improving gut barrier function and reducing inflammation. The company has launched a commercial dietary supplement targeting weight management and glucose control in Europe. Pharmaceutical programs are in earlier stages.[1][2][3]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on A-Mansia Biotech.